Mirion Technologies, Inc.

Mirion Technologies, Inc. is a global leader in radiation safety, science, and medicine, providing comprehensive detection, measurement, analysis, and monitoring solutions. The company's mission is to leverage its expertise in ionizing radiation for the benefit of humanity, fostering innovations that offer critical protection and harness radiation's transformative potential across diverse end markets. Mirion is headquartered in Atlanta, Georgia, USA.

The company operates through two primary business groups: Mirion Technologies and Mirion Medical. The Mirion Technologies group focuses on nuclear and safety, delivering radiation safety technologies and expertise for sectors such as nuclear energy, defense, research, industrial, and government. Its product portfolio includes spectroscopy and scientific analysis systems, health physics and radiation safety instruments, radiation monitoring systems, reactor instrumentation, and camera systems. The Mirion Medical group is dedicated to enhancing healthcare delivery and safety, with solutions spanning nuclear medicine, radiation therapy quality assurance, occupational dosimetry, and diagnostic imaging.

Thomas Logan serves as the Founder, Chairman, and Chief Executive Officer of Mirion Technologies. In recent news, the company hosted its inaugural Mirion Connect EMEA/APAC conference in Brussels in September 2026 and announced a validated Adaptive QA Solution for radiotherapy in collaboration with Siemens Healthineers. Mirion's Crew Active Dosimeters have also been selected for NASA's Artemis II mission. The company made several executive appointments in February 2026, including a Chief Nuclear Officer and a Chief Artificial Intelligence & Digital Officer, to accelerate strategic growth. While Mirion's stock reached a 52-week low in September 2026, analysts generally maintain a "Moderate Buy" consensus rating, projecting significant upside potential. The company reported increased revenue in the second quarter of 2026, largely driven by acquisitions, and reaffirmed its full-year guidance.